ATC codes: H01CB02
Acromegaly or pituitary gigantism ICD11 code: 5A60.0
Medicine type
Chemical agent
List type
Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate) ; 0.1 mg per mL in 1 mL vial (immediate-release, as acetate) ; 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
EML status history
First added in 2023 (TRS 1049)
Adolescents and adults
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of octreotide immediate-release and modified-release injections on the complementary list of the EML for use in the management of gigantism and acromegaly in adults with growth hormone-producing tumours. The Committee noted that transsphenoidal surgery is the treatment of first choice for this condition but accepted that pharmacological treatment with somatostatin analogues is an effective alternative in situations where surgery is not possible or available. The Committee did not recommend the inclusion of lanreotide depot injection either as an individual listing or as a therapeutic alternative to octreotide, because it was not shown to be superior to octreotide, is more expensive, and unlike octreotide, is not yet available as generics.